Valuation dashboard for Mirum Pharmaceuticals, Inc. (MIRM) with P/E N/A, P/B -565.87, EV/EBITDA -7.92 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Analysis Summary
Trailing-twelve-month margins: gross margin 81.7%, operating margin -17.4%, net margin -139.2%.
At the current price of $97.37, MIRM has negative trailing earnings (P/E not meaningful) and an ROE of -410.20%. Market capitalisation stands at $5.9B.
Balance sheet quality for MIRM: current ratio of 2.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -565.87 |
| EV / EBITDA | -7.92 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3045.38 |
| vs Current Price | -3227.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.80 | -34.1% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% | |
| SLNO | Soleno Therapeutics, Inc. | $2.8B | |||
| ADMA | ADMA Biologics, Inc. | $2.1B | 12.55 | 5.05 | 30.8% |
Price
| Price | $97.37 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -410.20% |
| Return on Invested Capital | -13.09% |
| Return on Assets | -82.32% |
| Gross Margin | 81.70% |
| Operating Margin | -17.42% |
| Net Margin | -139.18% |
Related companies: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explore sector: Healthcare · Biotechnology
More sections of MIRM: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks